The Neuroscience of Being Human

The Neuroscience of Polydrug Use

How combinations of substances produce pharmacological interactions that no single drug profile can predict, why some pairings are additive and others synergistic, what makes opioid-benzodiazepine and opioid-stimulant combinations the leading drivers of overdose mortality, and what the neuroscience reveals about a pattern of use that is now the rule rather than the exception

1,620-word article with 8 Harvard references.

The pharmacology of combination: additive, synergistic, antagonistic

When two drugs are present in the body simultaneously, their effects can combine in three broad ways. Additive interactions produce a combined effect equal to the sum of the individual effects: two depressants of equal potency together produce roughly twice the depression of either alone. Antagonistic interactions occur when one drug reduces the effect of another, either by competing for the same receptor or by activating an opposing system. Synergistic interactions are the most pharmacologically interesting and the most clinically dangerous: the combined effect exceeds the sum of the individual effects, sometimes by a wide margin.

Synergy typically arises when two substances act through different but converging mechanisms on the same physiological end-point. Two drugs that depress respiration by acting on different receptor systems can produce respiratory failure at doses well below those at which either drug alone would be lethal. The brain has multiple parallel mechanisms for maintaining vital functions; when two of those mechanisms are simultaneously suppressed, the redundancy that would normally protect against failure is gone. Most polydrug overdose deaths reflect this principle, not the toxicity of any single substance involved (Jones et al., 2012).

Opioids and benzodiazepines: the synergy that drives prescription overdose

Opioids depress respiration by acting on mu-opioid receptors in the brainstem respiratory centres, reducing the responsiveness of the respiratory drive to rising carbon dioxide. Benzodiazepines depress respiration through positive allosteric modulation of GABA-A receptors, reducing the excitatory drive to the same brainstem circuits. The two mechanisms converge on the same neuronal populations from different directions. Their combined effect on respiratory drive is markedly greater than the additive prediction.

Park et al. (2015), analysing prescription patterns and overdose mortality data, documented that the rise in overdose deaths in the United States during the 2000s was driven substantially by the combination of opioid and benzodiazepine prescribing. Patients prescribed both drug classes simultaneously had overdose mortality rates many times higher than those prescribed either class alone, after adjustment for indication and severity. The clinical guidance that has subsequently emerged, avoid combined opioid-benzodiazepine prescribing where possible and use the lowest effective dose of each when combination is necessary, reflects the pharmacological reality that the receptors do not care whether the drugs were obtained legally. The synergy is the same.

Opioids and stimulants: the new phase of the overdose crisis

The most recent phase of the North American overdose crisis has been characterised by a marked increase in deaths involving combinations of synthetic opioids, particularly fentanyl, with stimulants such as cocaine and methamphetamine. Hedegaard et al. (2020), reporting US national mortality data, documented that stimulant-involved overdose deaths rose more than tenfold over the preceding decade, with the majority involving co-detection of opioids. The combination is often unintentional: stimulants supplied through illicit markets are increasingly contaminated with fentanyl, and users seeking cocaine or methamphetamine may not know they are also consuming opioids.

The pharmacology of intentional opioid-stimulant combination, the so-called speedball or goofball pattern, exploits the experiential complementarity of the two drug classes: the stimulant produces euphoria and energy, the opioid blunts the anxious overstimulation that high-dose stimulants can produce. The neurochemistry, however, is unforgiving. The stimulant elevates heart rate, blood pressure, and metabolic demand. The opioid depresses respiration, reducing oxygen delivery. The cardiovascular system is being asked to work harder while the respiratory system is being shut down. The user, sedated by the opioid, cannot perceive the warning signals of dangerous oxygenation. Death from this combination often occurs without the user appearing distressed before consciousness is lost.

Cocaethylene: the only metabolite that requires two drugs to exist

When cocaine and alcohol are present in the body simultaneously, the liver enzyme carboxylesterase produces cocaethylene, an ethyl ester of benzoylecgonine that is pharmacologically active in its own right. Cocaethylene is a potent dopamine reuptake inhibitor with affinity for the dopamine transporter comparable to cocaine itself, but with a substantially longer half-life. Farré et al. (1997) characterised the pharmacokinetics and demonstrated that cocaethylene production prolongs the cocaine-like high and amplifies the cardiovascular effects of the original cocaine dose.

Cocaethylene is also more cardiotoxic than cocaine alone. Epidemiological studies have associated cocaine-alcohol combination use with substantially increased risk of sudden cardiac death compared with cocaine use alone, an effect that is attributed at least in part to cocaethylene's prolonged action on cardiac sodium channels and its contribution to coronary vasospasm. The combination that many users find subjectively pleasant, the sustained alertness of cocaine smoothed by the disinhibition of alcohol, is the combination that produces a metabolite with no other route of formation, a metabolite that prolongs and intensifies the cardiotoxic effects of both parent drugs.

Harm reduction in a polydrug world

The clinical and public health response to polydrug use has lagged behind the pharmacological reality. Treatment systems are typically organised by primary substance: alcohol services, opioid services, stimulant services. Drug education frequently focuses on individual substances. Yet the modal user, particularly in younger cohorts and in nightlife and festival populations, is consuming combinations whose interaction profiles are not adequately addressed by single-substance information.

Harm reduction organisations have increasingly emphasised combination-aware messaging: avoiding the most dangerous synergies (opioids with any other depressant), spacing rather than overlapping doses where combination is intended, testing substances for fentanyl contamination where the local supply is implicated, and maintaining naloxone access in any setting where opioids may be present whether the user believes they are using opioids or not. The neuroscience supports each of these. Synergistic depression is more dangerous than additive. Sequential dosing reduces peak overlap. Contaminated supply turns single-substance use into involuntary polydrug use. Naloxone reverses opioid respiratory depression and is one of the few pharmacological interventions in the field that reliably saves lives.